(Natural News) As if suffering from cancer weren’t bad enough on its own, a new study has found that nearly two-thirds of the cancer drugs that gained authorization from the European Medicines Agency (EMA) from 2009 to 2013 did not offer any clear proof that they would extend or improve patients’ lives.

The study, which was carried out by researchers from King’s College Londonand the London School of Economics and Political Science, revealed that most of the cancer drugs approved by the body rely on surrogate measures, which are not reliable predictors of a patient’s quality of life or survival.

Lead author Dr. Courtney Davis commented: “When expensive drugs that lack robust evidence of clinical benefit are approved and reimbursed within publicly funded healthcare systems, individual patients may be harmed and public funds wasted.”

In other words, cancer patients and the population, in general, suffer as…